NDAC Chair
This article was originally published in The Tan Sheet
Executive Summary
An "Appointed Chair" for the Nonprescription Drugs Advisory Committee will run meetings until a final selection is made for a permanent chair, according to FDA. Previous NDAC Chairman Alastair Wood, MD, concluded his term May 31. Wood will begin his role as a managing director at the New York-based private equity firm Symphony Capital in September (1"The Tan Sheet" May 8, 2006, p. 3) A permanent Chair normally is selected from the committee...
You may also be interested in...
NDAC’s Wood Departs FDA Committee; Joins Private Investment Firm
Nonprescription Drugs Advisory Committee Chairman Alastair Wood, MD, will depart NDAC in May and take a position at New York-based private equity firm Symphony Capital, the company announced May 1
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.